{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00822783",
      "orgStudyIdInfo": {
        "id": "CIGE025A2412"
      },
      "organization": {
        "fullName": "Medical University of Vienna",
        "class": "OTHER"
      },
      "briefTitle": "Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients",
      "officialTitle": "An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis."
    },
    "statusModule": {
      "statusVerifiedDate": "2009-01",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2001-10"
      },
      "completionDateStruct": {
        "date": "2003-04"
      },
      "studyFirstSubmitDate": "2009-01-13",
      "studyFirstSubmitQcDate": "2009-01-13",
      "studyFirstPostDateStruct": {
        "date": "2009-01-14",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2009-01-13",
      "lastUpdatePostDateStruct": {
        "date": "2009-01-14",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "leadSponsor": {
        "name": "Medical University of Vienna",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "Elevated levels of immunoglobuline E in blood are said to promote the occurence of atopic dermatitis; in fact, many patients with atopic dermatitis have high IgE levels. This study tried to explore whether the depletion of IgE from blood and skin might result in a change of immunological parameters and might alter the clinical course of the disease."
    },
    "conditionsModule": {
      "conditions": [
        "Atopic Dermatitis"
      ],
      "keywords": [
        "Serum IgE levels",
        "inflammatory cells in the skin",
        "inflammatory cells in the blood",
        "IgE",
        "IgE depletion",
        "atopic dermatitis",
        "atopic eczema",
        "Omalizumab"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ]
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Omalizumab",
          "type": "ACTIVE_COMPARATOR",
          "interventionNames": [
            "Drug: Omalizumab"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Omalizumab",
          "armGroupLabels": [
            "Omalizumab"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* aged between 12 and 60 years\n* clinical diagnosis of AD (criteria of Hanifin and Rajka, 1980)\n* serum IgE between 30 and 1,300 IU/ml\n* at least one significantly positive RAST\n* a positive skin prick test of the same specificity as the RAST\n* an Investigator's Global Assessment Score of 2 or more at randomization\n* stable AD, as defined as active AD (IGA 2 or more) for \\> 9 months per year\n* signed informed consent.\n\nExclusion Criteria:\n\n* pregnant or nursing females or women of childbearing potential who did not use a reliable contraceptive method\n* treatment with omalizumab within the last 12 months before study treatment\n* known hypersensitivity to any ingredients of omalizumab or omalizumab- related drugs\n* elevated serum IgE levels for reasons other than atopy\n* ongoing immunotherapy\n* use of long-acting antihistamine astemizol within 3 months prior to visit1\n* use of medium-acting antihistamines (e.g. loratadine, cetirizine) within 5 days prior to visit 1\n* use of short-acting antihistamines (e.g. diphenhydramin, terfenadine) within 3 days prior to visit 1\n* use of zafirlukast or other leukotriene receptor inhibitors and zileuton or other 5-lipoxygenase enzyme inhibitors within 3 days prior to visit 1\n* use of phototherapy or systemic therapy that is known or suspected to have had an effect on AD within 1 month prior to first application of study medication\n* treatment with topical therapy (other than hydrocortisone 1%) that is known or suspected to have had an effect on AD within 14 days prior to first application of study medication\n* use of systemic steroids (oral, intravenous, including intraarticular and rectal) within one month prior to first application of study medication. (Patients on a stable maintenance dose of inhaled steroids were allowed to participate)\n* use of systemic antibiotics within 2 weeks prior to first application of study medication\n* use of tranquilizers, hypnotic agents or tricyclic antidepressants within 2 weeks prior to the start of the study\n* immunocompromised patients or patients having a history of malignant disease\n* concurrent skin diseases\n* active bacterial, viral or fungal infections that required treatment with a prohibited medication\n* a history of recurrent herpes simplex infection having active lesions at baseline\n* tinea corporis / tinea cruris\n* clinically significant laboratory abnormalities\n* a history of noncompliance to medical regimens and patients who were considered potentially unreliable\n* evidence of drug or alcohol abuse or other factors limiting ability to fully cooperate\n* any condition or prior/continuing treatment which, in the opinion of the investigator, should have rendered the patient ineligible for the study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Austria.",
          "city": "Vienna, Waehringer Guertel 18-20",
          "zip": "1090 Vienna",
          "country": "Austria",
          "geoPoint": {
            "lat": 48.20849,
            "lon": 16.37208
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "16384758",
          "type": "BACKGROUND",
          "citation": "Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006 Jan;54(1):68-72. doi: 10.1016/j.jaad.2005.09.030. Epub 2005 Nov 28."
        },
        {
          "pmid": "16021135",
          "type": "BACKGROUND",
          "citation": "Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005 Aug;53(2):338-40. doi: 10.1016/j.jaad.2005.02.014."
        },
        {
          "pmid": "7759866",
          "type": "BACKGROUND",
          "citation": "Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol. 1995 Jun 15;154(12):6285-90."
        },
        {
          "pmid": "9743330",
          "type": "BACKGROUND",
          "citation": "Maurer D, Fiebiger E, Reininger B, Ebner C, Petzelbauer P, Shi GP, Chapman HA, Stingl G. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol. 1998 Sep 15;161(6):2731-9."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}